Gilead Sciences Inc Shares Perform Better 

Gilead Sciences Inc. shares increased -1.47% which is 0.77% higher to $71.71 Monday. This proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, -1.07% rising 0.26% to 4,479.71 and the Dow Jones Industrial Average DJIA, -1.08% rising 0.31% to 35,625.40.

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $71.39, which the company reached on August 13th.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson JNJ, -1.27% rose 0.90% to $177.84, Merck & Co. Inc. MRK, -1.32% rose 1.58% to $77.93, and AbbVie Inc. ABBV, -1.98% rose 1.66% to $118.41.

Gilead Sciences Inc trading volume (8.9 M) eclipsed its 50-day average volume of 6.1 M.This was the stock’s fifth consecutive day of gains. The company was in 65 hedge funds’ portfolios at the end of March. The all-time high for this statistic is 93. The shareholders have witnessed a decrease in enthusiasm from smart money of late. There were 72 hedge funds in our database with GILD holdings the end of December.

Investment company Axiom Investment Management LLC buys Gilead Sciences Inc, Alibaba Group Holding, ARK Fintech Innovation ETF, Impinj Inc, Exelixis Inc, sells Beyond Meat Inc, The Lovesac Co, Farfetch, Nucor Corp, Parker Hannifin Corp during the 3-months ended 2021Q2. As of 2021Q2, Axiom Investment Management LLC owns 156 stocks with a total value of $129 million.